Skip to main content
News Icon

COVIMMUNE being funded

A new consortium COVIMMUNE under the direction of Prof. Eicke Latz, speaker of the cluster of Excellence ImmunoSensation2 is being funded with around 2 Million Euros by the Federal Ministry of Education and Research (BMBF). The project "Understanding divergent host reactions to SARS-CoV-2 infections by precision immunology" (COVIMMUNE) brings together clinical researchers at the University Hospital Bonn who are involved in COVID-19 patient care with basic scientists with immunological expertise from the University of Bonn.

"We want to find out the connection between the mechanisms of the immune response to the SARS-CoV-2 infection and the clinical course of the disease," says Prof. Dr. Eicke Latz. Around two dozen personalities from disciplines such as virology, internal medicine, intensive care medicine, pulmonology, neurology, immunology, blood coagulation, bioinformatics and systems biology are involved. Together they want to contribute to a better understanding of the different course of the disease in SARS-CoV-2 infections. Prof. Natalio Garbi heads the sub-project of the consortium on adaptive immunity. He says: "We want to test whether the interaction of the innate and the acquired (adaptive) immune response is the key to eliminating the infection and developing long-term immunity without long-term health consequences."

The aim is to find out how the SARS-CoV-2 virus can trigger a misdirected immune response and what role this plays in severe COVID-19 disease courses. Furthermore, a clinical study will investigate which factors cause long-term damage to the lungs and the nervous system. Prof. Dr. Michael Heneka, whose sub-project in the consortium is looking at the secondary diseases of the lungs and the central nervous system caused by COVID-19, says: "It is not yet well understood how infection with the SARS-CoV-2 virus can trigger such secondary diseases. We want to examine these relationships in a clinical study in order to be able to offer better treatment options."


Contact

Prof. Dr. Eicke Latz

Institute of Innate Immunity, University of Bonn

Phone: 0228/287-51223

E-Mail: eicke.latz@uni-bonn.de

Related news

Prof. Dr. Kaan Boztug

News categories: Honors & Funding

Kaan Boztug awarded Novartis Prize

Prof. Dr. Kaan Boztug from the University Hospital Bonn (UKB) receives the Novartis Prize for Therapy-Relevant Immunological Research 2025. The expert in rare diseases of the immune system and blood formation conducted most of the research work that has now been honored in Vienna. His work was supported by an ERC Starting Grant (ImmunoCore, 2012-2018) and an ERC Consolidator Grant (iDysChart, 2019-2025), among others. The science prize, worth 10,000 € is divided into two parts this time and also goes to Prof. Dr. Evelyn Ullrich.
View entry
Gunther Hartmann and Christina Wuebben

News categories: Focus

An RNA key against viruses

Activating the body's antiviral defense system: A novel RIG-I ligand developed at the Medical Faculty of the University of Bonn and the University Hospital Bonn (UKB) helps the body to recognize and fight off certain viruses at an early stage. This molecular structure has potential for the prevention and treatment of viral infections. Based on the research results, there are now plans to develop and market an antiviral nasal spray to protect against viral respiratory infections.
View entry
members of the Bonn-Cumming Host-Directed Pandemic Therapeutics Program

News categories: Focus

Joining forces against future pandemics

Three days of scientific exchange, workshops, and new impulses: Until July 2, 2025, members of the Bonn-Cumming Host-Directed Pandemic Therapeutics Program are gathered at University Hospital Bonn (UKB) for a symposium to reflect on the current state of their research and discuss further steps. The joint program of the Cumming Global Centre for Pandemic Therapeutics at the University of Melbourne and of the University of Bonn aims to combat future pandemics with novel therapeutics.
View entry

Back to the news overview